

Eric Baudin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3448012/publications.pdf>

Version: 2024-02-01

72
papers

7,553
citations

71102

41
h-index

88630

70
g-index

72
all docs

72
docs citations

72
times ranked

6438
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	27.0	692
2	Genetic Testing in Pheochromocytoma or Functional Paraganglioma. <i>Journal of Clinical Oncology</i> , 2005, 23, 8812-8818.	1.6	612
3	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	21.4	560
4	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2018, 179, G1-G46.	3.7	559
5	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
6	Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3822-3828.	3.6	399
7	Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging. <i>Journal of Clinical Oncology</i> , 2005, 23, 70-78.	1.6	339
8	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 841-849.	3.6	274
9	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 426-435.	10.7	272
10	Prognostic Parameters of Metastatic Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 148-154.	3.6	205
11	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2796-2804.	3.6	187
12	Plasma Concentrations of o,pâ€²DDD, o,pâ€²DDA, and o,pâ€²DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1844-1851.	3.6	160
13	<i>SDHB</i> mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. <i>International Journal of Cancer</i> , 2014, 135, 2711-2720.	5.1	155
14	New therapeutic approaches for metastatic thyroid carcinoma. <i>Lancet Oncology</i> , The, 2007, 8, 148-156.	10.7	136
15	Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2012, 166, 451-458.	3.7	132
16	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
17	MANAGEMENT OF ENDOCRINE DISEASE: Cushingâ€™s syndrome due to ectopic ACTH secretion: an expert operational opinion. <i>European Journal of Endocrinology</i> , 2020, 182, R29-R58.	3.7	120
18	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1652-1664.	10.7	108

#	ARTICLE	IF	CITATIONS
19	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103
20	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4006-4012.	3.6	102
21	Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel. <i>Journal of Clinical Oncology</i> , 2010, 28, e401-e402.	1.6	95
22	Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (≥10%) Well-Differentiated Endocrine Carcinoma Staging. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 665-671.	3.6	93
23	THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2014, 171, R111-R122.	3.7	91
24	Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study. <i>Annals of Surgery</i> , 2018, 268, 158-164.	4.2	89
25	Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCO, GERCOR, UNICANCER, SFCE). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 101, 1-10.	0.784834	84
26	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
27	Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 371-381.	3.1	75
28	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4080-4088.	3.6	72
29	Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas. <i>Cancer</i> , 2007, 110, 265-274.	4.1	63
30	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1772-1780.	6.4	62
31	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019, 108, 54-62.	2.5	62
32	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. <i>Journal of Medical Genetics</i> , 2019, 56, 513-520.	3.2	60
33	The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 683-698.	3.2	58
34	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	7.1	57
35	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2010, 17, 797-807.	3.1	52
36	Transcatheter Arterial Chemoembolization for Liver Metastases in Patients with Adrenocortical Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1527-1532.	0.5	52

#	ARTICLE	IF	CITATIONS
37	FDG PET in the Management of Patients with Adrenal Masses and Adrenocortical Carcinoma. <i>Hormones and Cancer</i> , 2011, 2, 354-362.	4.9	51
38	Adrenocortical Carcinoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 411-434.	3.2	51
39	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. <i>European Journal of Endocrinology</i> , 2012, 166, 261-268.	3.7	50
40	Adrenocortical Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1194-1201.	3.7	47
41	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	3.6	44
42	Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors. <i>BMC Cancer</i> , 2019, 19, 66.	2.6	42
43	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	30.7	38
44	¹⁸ F-fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1941-1942.	6.4	32
45	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2890-2898.	3.6	30
46	Phase II Study of Plitidepsin 3-Hour Infusion Every 2 Weeks in Patients With Unresectable Advanced Medullary Thyroid Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 83-88.	1.3	27
47	Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches. <i>Oncotarget</i> , 2017, 8, 109924-109940.	1.8	25
48	Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer. <i>Endocrine</i> , 2021, 71, 434-442.	2.3	19
49	Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors. <i>Hormones and Cancer</i> , 2018, 9, 62-69.	4.9	18
50	Intervention in gastro-enteropancreatic neuroendocrine tumours. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 855-865.	2.4	16
51	Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. <i>Lung Cancer</i> , 2020, 148, 149-158.	2.0	16
52	Differentiated Thyroid Cancer in Children and Adolescents: Long Term Outcome and Risk Factors for Persistent Disease. <i>Cancers</i> , 2021, 13, 3732.	3.7	16
53	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
54	Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients. <i>Hormones and Cancer</i> , 2017, 8, 330-337.	4.9	15

#	ARTICLE	IF	CITATIONS
55	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	2.8	12
56	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 537-546.	2.5	12
57	Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4698-e4707.	3.6	10
58	¹⁸ F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. <i>Oral Oncology</i> , 2015, 51, 370-375.	1.5	9
59	FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. <i>Digestive and Liver Disease</i> , 2021, 53, 824-829.	0.9	9
60	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2726-2737.	3.6	8
61	Are we reproducible in measurement of NET liver metastasis?. <i>Digestive and Liver Disease</i> , 2017, 49, 1121-1127.	0.9	5
62	Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma. <i>Cancers</i> , 2022, 14, 2730.	3.7	5
63	Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient. <i>Annales D'Endocrinologie</i> , 2017, 78, 67-69.	1.4	4
64	Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study. <i>European Journal of Cancer</i> , 2019, 123, 92-100.	2.8	3
65	Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity?. <i>Neuroendocrinology</i> , 2021, 111, 139-145.	2.5	3
66	Dyslipidemia causes overestimation of plasma mitotane measurements. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150135.	0.5	3
67	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2167-e2176.	3.6	3
68	How effective is prophylactic thyroidectomy in asymptomatic multiple endocrine neoplasia type 2A?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 256-257.	2.8	1
69	Preoperative ultrasound mapping of the vagus nerve in thyroid surgery. <i>Gland Surgery</i> , 2022, 11, 91-99.	1.1	1
70	Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival. <i>Cancers</i> , 2022, 14, 2225.	3.7	1
71	A diffuse pruriginous erythemato-squamous rash. <i>Endocrine</i> , 2021, 74, 435-436.	2.3	0
72	Effects of vandetanib on body composition in patients with advanced medullary thyroid carcinomas: Results from a placebo-controlled study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5569-5569.	1.6	0